TRAW

+ Watchlist + Portfolio

Traws Pharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.54
52-Week Range: $0.43 – $3.27
Market Cap: $7.99M
P/E (TTM): —
EPS (TTM): -1.83
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: -5639.19%
Return on Assets: -90.09%
Gross Margin: 100.00%
Operating Margin: -717.82%
Profit Margin: 0.00%
Current Ratio: 0.43
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-10.35M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $5.52M

TRAW Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$226.00K	$226.00K	$226.00K	$2.79M
Research & Development	$11.41M	$11.43M	$12.85M	$12.14M
Selling, General & Admin	$8.45M	$9.09M	$12.29M	$8.52M
Operating Expenses	$19.85M	$20.52M	$25.14M	$20.66M
Operating Income	-$19.63M	-$20.30M	-$24.91M	-$17.88M
EBITDA	-$19.61M	-$20.28M	-$24.90M	-$17.81M
Pretax Income	-$18.96M	-$18.95M	-$166.52M	$9.17M
Net Income	-$18.96M	-$18.95M	-$166.52M	$9.17M
Diluted EPS	-22.75	-22.57	-35.21	0.82
Diluted Shares	836329	839554	1.55M	8.38M

TRAW Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$38.76M	$20.82M	$21.34M	$3.82M
Receivables	$29.00K	$18.00K	$1.76M	$3.79M
Current Assets	$39.35M	$22.66M	$24.95M	$7.98M
Total Assets	$39.37M	$22.68M	$24.96M	$10.62M
Current Liabilities	$8.05M	$9.22M	$11.53M	$11.15M
Total Liabilities	$11.06M	$12.01M	$56.59M	$11.25M
Retained Earnings	-$463.68M	-$482.63M	-$649.15M	-$639.98M
Shareholders' Equity	$28.31M	$10.67M	-$31.63M	-$629.00K
Working Capital	$31.30M	$13.44M	$13.42M	-$3.17M

TRAW Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.29M	-$17.93M	-$29.79M	-$18.18M
Capital Expenditure	—	-$14.00K	—	-$2.58M
Free Cash Flow	-$16.29M	-$17.95M	-$29.79M	-$20.77M
Depreciation & Amortisation	$14.00K	$16.00K	$12.00K	$61.00K
Stock-Based Compensation	$1.17M	$1.30M	$1.39M	$728.00K
Investing Cash Flow	$0.00	-$14.00K	-$3.65M	-$2.58M
Financing Cash Flow	$0.00	$0.00	$33.98M	$3.20M
Net Change in Cash	-$16.29M	-$17.95M	$536.00K	-$17.57M

TRAW Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$57.00K	$2.73M	$0.00	$0.00	$0.00
Research & Development	$2.51M	$2.29M	$2.31M	$5.04M	$4.91M
Selling, General & Admin	$2.75M	$1.69M	$1.74M	$2.33M	$2.03M
Operating Expenses	$5.26M	$3.98M	$4.05M	$7.37M	$6.95M
Operating Income	-$5.20M	-$1.25M	-$4.05M	-$7.37M	-$6.95M
EBITDA	-$5.20M	-$1.25M	-$4.04M	-$7.32M	-$6.90M
Pretax Income	$21.49M	-$915.00K	-$3.96M	-$7.44M	-$7.11M
Net Income	$21.49M	-$915.00K	-$3.96M	-$7.44M	-$7.11M
Diluted EPS	2.09	-0.11	-0.34	—	-0.53
Diluted Shares	7.22M	5.82M	8.82M	—	10.64M

TRAW Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$15.94M	$13.08M	$6.42M	$3.82M	$3.13M
Receivables	$1.65M	$1.32M	$1.99M	$3.79M	$1.69M
Current Assets	$18.86M	$15.37M	$9.63M	$7.98M	$5.67M
Total Assets	$19.06M	$15.62M	$12.44M	$10.62M	$8.16M
Current Liabilities	$10.40M	$7.35M	$7.89M	$11.15M	$13.21M
Total Liabilities	$13.06M	$7.36M	$7.90M	$11.25M	$13.47M
Retained Earnings	-$627.66M	-$628.58M	-$632.54M	-$639.98M	-$647.09M
Shareholders' Equity	$6.00M	$8.26M	$4.54M	-$629.00K	-$5.31M
Working Capital	$8.46M	$8.02M	$1.74M	-$3.17M	-$7.54M

TRAW Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.44M	-$5.98M	-$4.01M	-$2.76M	-$2.58M
Free Cash Flow	-$5.44M	-$5.98M	-$6.60M	-$2.76M	-$2.58M
Depreciation & Amortisation	$1.00K	$1.00K	$15.00K	$44.00K	$44.00K
Stock-Based Compensation	$161.00K	$105.00K	$135.00K	$327.00K	$634.00K
Investing Cash Flow	—	—	-$2.58M	$0.00	—
Financing Cash Flow	$13.00K	$3.10M	-$62.00K	$158.00K	$1.90M
Net Change in Cash	-$5.42M	-$2.88M	-$6.66M	-$2.60M	-$679.00K

Market Snapshot

About

Traws Pharma is a clinical-stage biopharmaceutical company developing treatments for neurological and psychiatric disorders. The company focuses on novel therapeutic approaches for conditions including depression, anxiety, and neurodegenerative diseases. Traws is advancing multiple drug candidates through preclinical and clinical development.